Fredun Pharmaceuticals (BOM:539730) Other Current Receivables: ₹9 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:539730 Fredun Pharmaceuticals Ltd BOM:539730
67 GF Score
Price ₹1,244.20
GF Value ₹537.27
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Fredun Pharmaceuticals Other Current Receivables?

Fredun Pharmaceuticals BOM:539730 +1.83% 67 Other Current Receivables is ₹9 Mil as of Mar. 2026. GuruFocus rates BOM:539730 with a GF Score™ of 67/100 and a GF Value™ of ₹537.27 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Fredun Pharmaceuticals's Other Current Receivables for the quarter that ended in Mar. 2026 was ₹9 Mil.

Fredun Pharmaceuticals's quarterly Other Current Receivables declined from Sep. 2025 (₹8.00 Mil) to Dec. 2025 (₹0.00 Mil) but then increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹8.71 Mil).

Fredun Pharmaceuticals's annual Other Current Receivables increased from Mar. 2024 (₹2.46 Mil) to Mar. 2025 (₹4.70 Mil) and increased from Mar. 2025 (₹4.70 Mil) to Mar. 2026 (₹8.71 Mil).

Fredun Pharmaceuticals Other Current Receivables Related Terms

Fredun Pharmaceuticals Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Fredun Pharmaceuticals's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fredun Pharmaceuticals Other Current Receivables Chart

Fredun Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.05 1.51 2.46 4.70 8.71

Fredun Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.70 0.00 8.00 0.00 8.71
BOM:539730
67GF Score
Fredun Pharmaceuticals Ltd BOM:539730
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fredun Pharmaceuticals Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of ₹9 Mil mean?
Fredun Pharmaceuticals (BOM:539730) has a Other Current Receivables of ₹9 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Fredun Pharmaceuticals and its competitors.
Is Fredun Pharmaceuticals' Other Current Receivables too high?
Fredun Pharmaceuticals' current Other Current Receivables is ₹9 Mil. Overall, Fredun Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fredun Pharmaceuticals' Other Current Receivables compare to ZTS?
Fredun Pharmaceuticals' Other Current Receivables of ₹9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Fredun Pharmaceuticals and its competitors. Fredun Pharmaceuticals's current Other Current Receivables is ₹9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fredun Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fredun Pharmaceuticals (BOM:539730) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹537.27, compared to a current price of ₹1,244.20 — trading 131.6% above its estimated fair value. The current Other Current Receivables is ₹9 Mil. Fredun Pharmaceuticals' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Fredun Pharmaceuticals (BOM:539730), the current Other Current Receivables is ₹9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fredun Pharmaceuticals (BOM:539730) Overvalued in 2026?

Based on GuruFocus' analysis, Fredun Pharmaceuticals stock appears to be overvalued. The current stock price of ₹1,244.20 is trading 131.6% above its estimated GF Value™ of ₹537.27. GuruFocus considers Fredun Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:539730:

  • Other Current Receivables: ₹9 Mil
  • GF Value™: ₹537.27 vs. price of ₹1,244.20 (131.6% above fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the BOM:539730 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fredun Pharmaceuticals Business Description

Address Ganpatrao Kadam Marg, Delisle Road, 11th Floor, Urmi Estate 95, Lower Parel (West), Mumbai, MH, IND, 400013
Fredun Pharmaceuticals Ltd in its Endeavour to move ahead has now ventured into manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with Animal Healthcare products also with products ranging from allopathic formulations to on field diagnostic kits, Company's main objective is to be a holistic healthcare provider. The group is dedicated to improving lives of people. The Company operates only in a single segment i.e. Pharmaceutical Segment. The company has presence in Domestic as well as International market. The company generates majority of revenue from Domestic market.
67GF Score

Get the complete analysis for BOM:539730

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,244.20
Price
₹537.27
GF Value